{"entity":{"id":"nct06126510","kind":"trial","name":"Clinical Study of VG161 in the Treatment of Advanced Bone and Soft Tissue Sarcoma","aka":[],"tldr":"A phase 2 trial of Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell) in sarcomas, run by CNBG-Virogin Biotech (Shanghai) Ltd., now recruiting.","summary":"Clinical Study of VG161 in the Treatment of Advanced Bone and Soft Tissue Sarcoma is a phase 2 interventional study registered as NCT06126510 by CNBG-Virogin Biotech (Shanghai) Ltd., with 40 participants planned, started 2023-07-18 and due to reach its primary completion in 2025-07-17. Interventions recorded: Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell).","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06126510","url":"https://clinicaltrials.gov/study/NCT06126510"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["sarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06126510","phase":"2","setting":"A Single-arm, Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of VG161 in the Treatment of Advanced Bone and Soft Tissue Sarcoma","sponsor":"CNBG-Virogin Biotech (Shanghai) Ltd.","enrolled":40,"outcomes":[]},"route":"/trials/nct06126510/","neighbours":{"cancer":[{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"}]}}